Search Results

Spotlight On Acute Myeloid Leukemia (AML)

Spotlight on Chronic Lymphocytic Leukemia (CLL)

2013 Leukemia Ball Entertainment Announcement

Update On Chronic Lymphocytic Leukemia (CLL)

Insight into Chronic Myeloid Leukemia (CML)

What’s on the Horizon for Chronic Lymphocytic Leukemia?

Edward Jones & The Leukemia & Lymphoma Society

What's on the Horizon for Chronic Myeloid Leukemia?

Living With Chronic Myeloid Leukemia (CML)

Early diagnosis and treatment of pre-leukemia

In the current study we propose, based on our preliminary results, that we can reliably identify pre-AML cases out of the many individuals with age related clonal hematopoiesis (ARCH) based on clinical parameters thereby limiting the population that needs to undergo molecular testing. We have also developed a predictive model that can identify pre-AML cases years before diagnosis. We now propose to utilize this knowledge to treat high-risk individuals with ARCH, at a time point before they have developed disease, by targeting the driving alterations most associated with AML development.

Targeting cathepsin G in acute myeloid leukemia

We developed a chimeric antigen receptor (CAR) targeting an epitope of the myeloid associated antigen cathepsin G that is processed and presented in the contest of the MHC complex in myeloid leukemic cells. T cells expressing the cathepsin G specific CAR (CG1.CAR) recognize HLA-A2+ myeloid target cells expressing cathepsin G. We intend to study efficacy and safety of CG1.CAR-T cells in preclinical models in preparation of a phase I clinical study in patients with relapsed/refractory AML.

Role of HLX in leukemia induction and maintenance

We and others have shown how HLX overexpression keeps blood cells more immature by blocking their differentiation and promoting their proliferation, a characteristic which is inherent to AML. However, whether there is a causative role of HLX in the induction of AML is still unclear. Hence, the aim of my study is to better understand, using genetically engineered mice models, retroviral models, and human AML patient samples, how HLX drives AML at molecular level. This study will uncover potential therapeutic strategies for AML treatment in future.

Living With Chronic Lymphocytic Leukemia (CLL)

Evolving Treatment Strategies in Pediatric Leukemia

Chronic Lymphocytic Leukemia 3D Model

.model-icon-key-mobile{ display:none;} @media only screen and (max-width: 767px) { .model-icon-key-desktop{ display: none;} .model-icon-key-mobile{ display: block;} }

This model contains the following chapters. Click the "Interact in 3D" button to begin.

• Healthy Bone Marrow
• Normal Blood Cell Production
• Proliferation of Cells and the Crowding Out of Normal Cells
• Signs and Symptoms

 

Chronic Myeloid Leukemia 3D Model

.model-icon-key-mobile{ display:none;} @media only screen and (max-width: 767px) { .model-icon-key-desktop{ display: none;} .model-icon-key-mobile{ display: block;} }

This model contains the following chapters. Click the "Interact in 3D" button to begin.

• Healthy Bone Marrow
• Normal Blood Cell Production
• Proliferation of Cells and the Crowding Out of Normal Cells
• Signs and Symptoms

Acute Myeloid Leukemia 3D Model

.model-icon-key-mobile{ display:none;} @media only screen and (max-width: 767px) { .model-icon-key-desktop{ display: none;} .model-icon-key-mobile{ display: block;} }

This model contains the following chapters. Click the "Interact in 3D" button to begin.

• Healthy Bone Marrow
• Normal Blood Cell Production
• Proliferation of Cells and the Crowding Out of Normal Cells
• Signs and Symptoms

Highlights in Therapy: Hairy Cell Leukemia

Eevie: Continuing to Defy the Odds

Diagnosed at birth with a rare leukemia, Eevie had a 17 percent chance of making it to age 2. Now 18 months old, she continues to defy the odds as she marks the same milestones as others her age. Her parents, Brynne and Ryan, report that she is all smiles and is a very happy (and thankfully ornery) little girl. Eevie was assessed and dismissed from physical therapy as she is "right on track." She is walking around the house, trying to put on Mommie's shoes, and is saying multiple words. Eevie loves to make animal noises (mainly the tiger, her inspirational mascot) and growls often!

Meet the Researcher: Omar Abdel-Wahab, MD

This is part of a periodic series of Q&A’s with LLS-funded researchers. Dr. Abdel-Wahab of Memorial Sloan Kettering Cancer Center focuses on an area of research called epigenetics – chemical modifications that regulate (switch on and off) gene activity. He is studying how these processes drive the development of acute myeloid leukemia and other blood cancers. He currently holds a Career Development Program grant from LLS, a program that supports scientists earlier in their careers.

Q. What is the focus of your research and its primary goal?

Just Diagnosed? LLS Can Help

Finding out you have blood cancer can bring on a whirlwind of emotions and a plethora of questions. No one expects to get such a diagnosis and there isn’t anything you can do to prepare.  

Regardless of how you came to your diagnosis, most people report not having absorbed a lot of information after hearing the word “cancer." The vocabulary may seem like a foreign language, and the need for support  can be tremendous.

Against All Odds, Eevie Turns 1!

A first birthday is always a big occasion, but for Eevie, it's taken on a whole new meaning. She was born with a rare leukemia that gives her a 17 percent chance of surviving to age 2. Even her parents weren't sure she would make it this far. "We didn't think she would still be here. The odds were never in her favor," said her mom, Brynne. Eevie was born with congenital acute lymphoblastic leukemia (ALL), an extremely rare condition affecting 1 in 5 million newborns.

Blood cancers that cause high monocytes: Understanding the connection

Table of contents: